Welcome to our dedicated page for NewAmsterdam Pharma Co N.V. SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pharma Co N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pharma Co N.V.'s regulatory disclosures and financial reporting.
NewAmsterdam Pharma (NAMS) furnished an update on November 5, 2025, announcing corporate updates and financial results for the quarter ended September 30, 2025. The company also posted an updated corporate investor presentation on its website.
Both the press release and the investor presentation were furnished as Exhibits 99.1 and 99.2, respectively, and are not deemed filed under the Exchange Act or incorporated by reference, except as expressly stated in future filings.
James N. Topper, a director of NewAmsterdam Pharma Co N.V. (ticker: NAMSW), reported a purchase on Form 4. The filing shows a transaction on 09/15/2025 acquiring 660 ordinary shares at a weighted average price of $23.6953. The filing lists two holdings following the reported transaction: 3,028,524 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. Footnotes state the reported price is a weighted average from multiple purchases priced between $23.46 and $23.75. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Topper on 09/17/2025.